Journal
CARDIOVASCULAR PATHOLOGY
Volume 18, Issue 3, Pages 140-147Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.carpath.2008.03.001
Keywords
Fibrates; Tissue factor; Atherosclerosis
Categories
Funding
- University of Lille 2 [EA 2693/IFR114]
- Centre Hospitalier et Universitaire de Lille [AO98/1956]
- Inserm
- Region Nord-Pas de Calais
- Feder [ESPRI-ERI9, R04026EE]
- Fondation Coeur et Arteres
Ask authors/readers for more resources
Background: Fibrates are peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists which modulate many aspects of lipoprotein metabolism and inflammation. They have been recently demonstrated to inhibit in vitro expression of tissue factor (TF), the main initiator of blood coagulation, which probably plays a pivotal role in thrombotic complications after plaque rupture. We investigated whether a 4-week fenofibrate treatment might affect the TF expression and cellular modifications in angioplasty-induced rabbit plaque rupture. Methods: After plaque rupture by balloon angioplasty in atheromatous rabbits, animals were randomized in an untreated group or a group receiving fenofibrate. The TF content of arterial wall and the histological modifications were analyzed after 4 weeks. Results: Fenofibrate decreased in vivo TF expression (-42%, P<.05) and plaque cholesterol content (P<.01) in iliac arteries. Fenofibrate significantly improved the reendothelialization process by 51% (P<.05) and modified cellular distribution in the plaque toward increased stabilization. Conclusions: These data indicate that the PPAR alpha-activator fenofibrate reduces plaque thrombogenicity and accelerates endothelial regrowth which, altogether, might improve plaque stability. These effects may underlie the preventive effects of fibrate therapy in atherosclerosis complications. (C) 2009 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available